News

News Subscription

May 16. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
May 03. 2024
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
Read more
Download
Apr 24. 2024
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 09. 2024
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
Read more
Download
Apr 04. 2024 / Ad hoc announcement
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
Read more
Download
Mar 11. 2024
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Feb 13. 2024 / Ad hoc announcement
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Read more
Download
Jan 19. 2024
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
Read more
Download
Jan 15. 2024
Basilea announces acquisition of preclinical antibiotics program from Spexis
Read more
Download
Jan 05. 2024
Basilea provides portfolio status update
Read more
Download